Multiple mechanisms by which SGLT2 inhibitors contribute to euglycemic diabetic ketoacidosis include triggering glucagon secretion in pancreatic Î±-cells, lowering urinary elimination of ketones, and initiating carbohydrate deprivation despite normal glucose levels.